To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema
Phase 1
- Conditions
- Resistant Cystoid Macular Edema
- Interventions
- Drug: Intravitreal injection of Avastin
- Registration Number
- NCT00371111
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Cystoid macular edema (CME) is one of the common causes of vision loss in patients with UveitiS .Triamcinolone has been effectively used in reducing CME and improving the vision. Also there are some documents which recommend Bevacizumab(avastin) could reduce macular edema. This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.
- Detailed Description
This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Uveitic CME
- Uveitic CME refractory to routine treatment
- Vision better than 5/200 and worse than 20/50
Exclusion Criteria
- Mono- Ocular patients
- History of vitrectomy
- Glaucoma or ocular hypertension
- History of other retinal disease that can cause macular edema
- Pregnancy
- Significant media opacity
- Vision better than 20/50
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Intravitreal injection of Triamcinolone Intravitreal injection of Triamcinolone 2 Intravitreal injection of Avastin Intravitreal injection of Avastin
- Primary Outcome Measures
Name Time Method Resorbed CME in OCT every 3 month Resorbed CME in clinical examination Every 3 month
- Secondary Outcome Measures
Name Time Method need to retreatment when ever needed
Trial Locations
- Locations (1)
Masoud Soheilian , MD
🇮🇷Tehran, Iran, Islamic Republic of